@itsmamabrit's 120-pound GLP-1 weight loss claims checked

What did @itsmamabrit actually say?

She kept it blunt. The claim is 120 pounds lost over one year using a GLP-1 medication as "a tool." Beyond the numbers, her actual advice was essentially: stop overthinking it and start. "Pick your hard" is the core message, which frames obesity treatment as a choice between discomfort types rather than a medical decision. The transcript cuts off mid-sentence, so we're missing her full take, but the caption does the heavy lifting, calling GLP-1s "not a get skinny quick" and framing the loss as a lifestyle change.

She's not making pharmaceutical claims. She's not dosing anyone. She's sharing a personal result and attaching it to a sponsor hashtag for Amble, a telehealth platform. That context matters when evaluating whether this is medical advice or a before-and-after testimonial. It's the latter, but the scale of the result and the reach of the video (435K views) means the claims deserve scrutiny.

Does the science back this up?

A 120-pound loss in 12 months on a GLP-1 is on the high end of what clinical data shows, but it's not impossible, especially at higher starting weights. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg produced an average 14.9% body weight reduction over 68 weeks. For someone starting at, say, 300 pounds, that's roughly 45 pounds on average, not 120.

But averages obscure outliers. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) for tirzepatide showed some participants losing over 25% of body weight. At 300 pounds, that's 75 pounds. At 400-plus pounds, 120 pounds in a year becomes statistically plausible. Tirzepatide, which targets both GIP and GLP-1 receptors, consistently outperforms semaglutide in head-to-head comparisons (Frias et al., 2021, NEJM). We don't know which drug she used, which limits how precisely we can evaluate her result.

What did they get wrong (or right)?

She got the framing right. Calling a GLP-1 "a tool" rather than a cure is accurate and clinically responsible. The STEP 4 trial (Rubino et al., 2021, JAMA) showed that people who stopped semaglutide regained two-thirds of their lost weight within a year, which is exactly the kind of context that the "not a get skinny quick" framing is pointing toward, even if she never cites the study.

What's missing is the full picture of how hard 120 pounds in a year actually is to sustain. Rapid weight loss at that scale can involve meaningful muscle loss alongside fat loss, and GLP-1s don't automatically preserve lean mass. A 2023 analysis (Wilding et al., Diabetes, Obesity and Metabolism) noted that roughly 25-40% of weight lost on semaglutide may come from lean tissue, not just fat. The "body recomp" hashtag in her caption suggests she's aware of this, but the transcript doesn't address it at all.

• Correct: GLP-1s require lifestyle change to sustain results
• Correct: Results take time and involve setbacks
• Missing: Muscle loss risk during rapid weight loss on GLP-1s
• Missing: Weight regain data after discontinuation

What should you actually know?

120 pounds in one year is a real outcome for some people on GLP-1 therapy, but it's nowhere near the average. If you're watching this video and calculating what that would mean for your body, pump the brakes. Clinical trial averages land between 10% and 22% body weight loss depending on the drug, dose, and duration. Your result will depend on starting weight, adherence, diet, activity, and whether you're using semaglutide or tirzepatide.

More important: the sustainability question is what most viral weight loss content ignores entirely. The STEP 4 data is not a minor footnote. It means GLP-1 therapy, for most people, is indefinite, not a one-year course. Insurance coverage, cost, and supply chain issues make that a real-world problem that "just fucking start" doesn't solve. Talk to a licensed provider about what the maintenance phase actually looks like before you focus on the headline number.